Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIPS trial of benralizumab in children with eosinophilic diseases
NL-OMON61311Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES) and eosinophilic disease (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events and Serum concentrations of benralizumab. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)hypereosinophilic syndrome (HES)eosinophilic disease
Beyond the preview
Go deeper on NL-OMON61311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61311.